Please login to the form below
Lilly names Plowman as oncology research chief
Eli Lilly has selected Greg Plowman, formerly senior director at Roche Group's Genentech, to lead its oncology research efforts
Eli Lilly and Company has appointed Greg Plowman as the vice president, oncology research and senior vice president of ImClone Systems research.
Plowman will oversee the oncology research efforts of Lilly and its subsidiary, ImClone. Plowman will be based at ImClone's Alexandria Center for Life Science in New York City, US.
Plowman served as a senior director in research for six years at Genentech, a member of the Roche Group. He has 25 years of experience in cancer research including leadership roles at Oncogene, Sugen, Exelixis and Genentech, which became part of Bristol-Myers Squibb, Pharmacia and Roche.
Lilly acquired ImClone in 2008, broadening its portfolio and strengthening its oncology pipeline and biotech capabilities. The company has one of the largest clinical-stage pipelines of potential cancer medicines in the industry with more than 30 molecules.
Share
Related Hub content
Subscribe to our email news alerts
- No “White Space” Between Live Meetings; the top 10 benefits of virtual advisory boards
- Building trust with HCPs: 6 takeaways from our industry webinar
- Eli Lilly and PRISM BioLab enter drug discovery collaboration worth over $660m
- NHS to offer stem cell transplants to patients living with rare blood disorder
- First WHO Global Clinical Trial Forum develops joint vision to improve clinical research
- Merck shares positive phase 3 results for investigational pneumococcal vaccine in adults
No results were found
PMHub
Say Communications
We focus on what matters most…. Driven by insight, expertise and fresh thinking, our award-winning communications programmes are designed to...
Latest intelligence
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
- The problem with clinical trials (and how virtual insight-gathering can help)
- While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....
- The rise of digital healthcare – fuelled by open innovation in healthtech hubs
- How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of drug development...
